市場調査レポート

商品コード

1701010

リキッドバイオプシー市場規模、シェア、成長分析、製品別、循環バイオマーカー別、技術別、用途別、臨床応用別、サンプルタイプ別、エンドユーザー別、地域別-2025～2032年産業予測

Liquid Biopsy Market Size, Share, and Growth Analysis, By Product, By Circulating Biomarker, By Technology, By Application, By Clinical Application, By Sample Type, By End User, By Region - Industry Forecast 2025-2032

出版日: 2025年04月03日
発行: SkyQuest
ページ情報: 英文 219 Pages
納期: 3～5営業日

価格

PDF & Excel (Single User License)

USD 5,300 789,170円

レポートPDF・Excelを1 名様のみがご利用頂けるライセンスです。PDF・Excell内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します

PDF & Excel (Multiple User License)

USD 6,200 923,180円

レポートPDF・Excel2-5名様までがご利用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

PDF & Excel (Enterprise License)

USD 7,100 1,057,190円

レポートPDF・Excelを同一企業に所属の全世界の方にご使用頂けるライセンスです。PDF・Excel内のテキスト等のコピーは可能です。PDF・Excelの印刷は可能ですが、印刷したもののご利用はPDF・Excelのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=148.90円

全表示
概要
目次

概要

サンプル依頼リストに入れる

リキッドバイオプシーの世界市場規模は、2023年に76億米ドルと評価され、2024年の87億5,000万米ドルから2032年には269億5,000万米ドルに成長し、予測期間（2025～2032年）のCAGRは15.1％で成長する展望です。

リキッドバイオプシー市場は、がん罹患率の上昇、診断技術の進歩、低侵襲検査法へのシフトを原動力として、大きく成長する展望です。特にマルチがん早期発見（MCED）検査の継続的な研究により、市場拡大の新たな道が開かれつつあります。腫瘍の遺伝子変化を検出する能力で知られるリキッドバイオプシーは、FDAによるESR1変異乳がんに対するGuardant360 CDxの承認が証明しているように、標的治療を促進します。さらに、公的検診を推進する政府のイニシアチブの高まりは、血液や羊水のような生物学的液体を用いた非侵襲的検査の受け入れをさらに後押ししています。医療の需要が高まるにつれ、特に出生前検査において、この市場は今後数年間成長する可能性が高いです。

北米
- 米国
- カナダ
欧州
- ドイツ
- スペイン
- フランス
- 英国
- イタリア
- その他の欧州
アジア太平洋
- 中国
- インド
- 日本
- 韓国
- その他のアジア太平洋
ラテンアメリカ
- ブラジル
- その他のラテンアメリカ
中東・アフリカ
- GCC諸国
- 南アフリカ
- その他の中東・アフリカ

競合情報

上位5社の比較
主要企業の市場ポジショニング（2024年）
主要市場企業が採用した戦略
最近の市場動向
企業の市場シェア分析（2024年）
主要企業の企業プロファイル
- 企業の詳細
- 製品ポートフォリオ分析
- 企業のセグメント別シェア分析
- 収益の前年比比較（2022～2024年）
  主要企業プロファイル
  - F. Hoffmann-La Roche Ltd（スイス）
  - Thermo Fisher Scientific Inc.（米国）
  - Illumina, Inc.（米国）
  - Guardant Health, Inc.（米国）
  - Biocept, Inc.（米国）
  - Sysmex Corporation（日本）
  - Natera, Inc.（米国）
  - Biocartis Group NV（ベルギー）
  - Bio-Rad Laboratories, Inc.（米国）
  - OncoCyte Corporation（米国）
  - Adaptive BIoTechnologies Corporation（米国）
  - Angle PLC（英国）
  - Epic Sciences, Inc.（米国）
  - Neogenomics Laboratories（米国）
  - CellMax Life（米国）
  - Menarini-Silicon Biosystems（イタリア）
  - Lunglife AI Inc.（米国）

結論と提言

Product Code: SQMIG35J2060

Global Liquid Biopsy Market size was valued at USD 7.6 billion in 2023 and is poised to grow from USD 8.75 billion in 2024 to USD 26.95 billion by 2032, growing at a CAGR of 15.1% during the forecast period (2025-2032).

The liquid biopsy market is poised for significant growth, driven by the rising prevalence of cancer, advancements in diagnostic technology, and a shift towards minimally invasive testing methods. Continued research into liquid biopsy assays, particularly multi-cancer early detection (MCED) tests, is opening new avenues for market expansion. Liquid biopsies, known for their ability to detect genetic alterations in tumors, facilitate targeted therapies, as evidenced by the FDA's approval of Guardant360 CDx for ESR1 mutant breast cancer. Additionally, increasing government initiatives promoting public screening further boost acceptance of non-invasive tests using biological fluids like blood and amniotic fluid. As healthcare demands rise, especially in the context of prenatal testing, the market is well-positioned for growth in the coming years.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Liquid Biopsy market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Liquid Biopsy Market Segments Analysis

Global Liquid Biopsy Market is segmented by Product, Circulating Biomarker, Technology, Application, Clinical Application, Sample Type, End User and region. Based on Product, the market is segmented into Assay Kits, Instruments and Services. Based on Circulating Biomarker, the market is segmented into Circulating Tumor Cells, Circulating Tumor DNA, Cell-Free DNA, Extracellular Vesicles and Other Circulating Biomarkers. Based on Technology, the market is segmented into Multi-Gene Parallel Analysis Using NGS and Single-Gene Analysis Using PCR. Based on Application, the market is segmented into Cancer Applications and Non-Cancer Applications. Based on Clinical Application, the market is segmented into Therapy Selection, Treatment Monitoring, Early Cancer Screening and Recurrence Monitoring. Based on Sample Type, the market is segmented into Blood Samples and Other Sample Types. Based on End User, the market is segmented into Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End Users. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Liquid Biopsy Market

The global liquid biopsy market is significantly driven by the rising incidence of cancer worldwide. As more patients are diagnosed with various types, including lung, breast, colorectal, and prostate cancers, there is a growing demand for non-invasive diagnostic methods that facilitate early detection. Liquid biopsies offer a less painful alternative to traditional tissue biopsies, enabling real-time monitoring of tumor progression and assessing treatment responses. This innovative approach not only enhances patient outcomes but also improves survival rates, highlighting the importance of liquid biopsies in contemporary cancer care and fueling the expansion of this market segment.

Restraints in the Global Liquid Biopsy Market

The Global Liquid Biopsy market faces several significant restraints that hinder its widespread adoption. Despite the advantages it offers, the high costs associated with liquid biopsy diagnostic techniques pose a barrier, particularly in underdeveloped regions where healthcare budgets are limited. Additionally, many patients are unable to access treatments derived from liquid biopsy due to insufficient coverage by insurance plans and government health programs. Consequently, without clear reimbursement policies, healthcare providers may refrain from prescribing these tests, which further restricts market utilization and adoption rates. As a result, the growth potential of the liquid biopsy market remains constrained.

Market Trends of the Global Liquid Biopsy Market

The Global Liquid Biopsy market is increasingly leveraging Big Data Analytics and AI to enhance cancer diagnostics, driving significant innovation and growth within the sector. The integration of machine learning algorithms facilitates more precise classifications of tumors by analyzing distinct genetic alterations, enabling oncologists to make informed treatment decisions swiftly. This technological evolution is not only streamlining the diagnostic process but also leading to the discovery of novel biomarkers that enhance liquid biopsy accuracy. As the demand for minimally invasive testing continues to rise, the fusion of AI with traditional methodologies positions the liquid biopsy market for substantial expansion in the coming years.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2024
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Supply Chain Analysis
Patent Analysis
Regulatory Analysis
Technology Analysis
Case Studies

Global Liquid Biopsy Market Size by Product & Service & CAGR (2025-2032)

Market Overview
Assay Kits
Instruments
Services

Global Liquid Biopsy Market Size by Circulating Biomarker & CAGR (2025-2032)

Market Overview
Circulating Tumor Cells
Circulating Tumor DNA
Cell-Free DNA
Extracellular Vesicles
Other Circulating Biomarkers

Global Liquid Biopsy Market Size by Technology & CAGR (2025-2032)

Market Overview
Multi-Gene Parallel Analysis Using NGS
Single-Gene Analysis Using PCR

Global Liquid Biopsy Market Size by Application & CAGR (2025-2032)

Market Overview
Cancer Applications
- Lung Cancer
- Breast Cancer
- Colorectal Cancer
- Prostate Cancer
- Melanoma
- Other Cancers
Non-Cancer Applications
- Non-Invasive Prenatal Testing
- Organ Transplantation
- Infectious Disease Testing

Global Liquid Biopsy Market Size by Clinical Application & CAGR (2025-2032)

Market Overview
Therapy Selection
Treatment Monitoring
Early Cancer Screening
Recurrence Monitoring

Global Liquid Biopsy Market Size by Sample Type & CAGR (2025-2032)

Market Overview
Blood Samples
Other Sample Types

Global Liquid Biopsy Market Size by End User & CAGR (2025-2032)

Market Overview
Reference Laboratories
Hospitals & Physician Laboratories
Academic & Research Centers
Other End Users

Global Liquid Biopsy Market Size & CAGR (2025-2032)

North America (Product & Service, Circulating Biomarker, Technology, Application, Clinical Application, Sample Type, End User)
- US
- Canada
Europe (Product & Service, Circulating Biomarker, Technology, Application, Clinical Application, Sample Type, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Product & Service, Circulating Biomarker, Technology, Application, Clinical Application, Sample Type, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Product & Service, Circulating Biomarker, Technology, Application, Clinical Application, Sample Type, End User)
- Brazil
- Rest of Latin America
Middle East & Africa (Product & Service, Circulating Biomarker, Technology, Application, Clinical Application, Sample Type, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2024
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2024
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

F. Hoffmann-La Roche Ltd (Switzerland)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Illumina, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Guardant Health, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocept, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Sysmex Corporation (Japan)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Natera, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Biocartis Group NV (Belgium)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Bio-Rad Laboratories, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
OncoCyte Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Adaptive Biotechnologies Corporation (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Angle PLC (United Kingdom)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Epic Sciences, Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Neogenomics Laboratories (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
CellMax Life (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Menarini-Silicon Biosystems (Italy)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Lunglife AI Inc. (US)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments

リキッドバイオプシー市場規模、シェア、成長分析、製品別、循環バイオマーカー別、技術別、用途別、臨床応用別、サンプルタイプ別、エンドユーザー別、地域別-2025～2032年産業予測

Liquid Biopsy Market Size, Share, and Growth Analysis, By Product, By Circulating Biomarker, By Technology, By Application, By Clinical Application, By Sample Type, By End User, By Region - Industry Forecast 2025-2032

目次

イントロダクション

調査手法

エグゼクティブサマリー

市場力学と展望

主要市場の考察

リキッドバイオプシー市場規模：製品別&CAGR（2025～2032年）

リキッドバイオプシー市場規模：循環バイオマーカー別&CAGR（2025～2032年）

リキッドバイオプシー市場規模：技術別&CAGR（2025～2032年）

リキッドバイオプシー市場規模：用途別&CAGR（2025～2032年）

リキッドバイオプシー市場規模：臨床応用別&CAGR（2025～2032年）

リキッドバイオプシー市場規模：サンプルタイプ別&CAGR（2025～2032年）

リキッドバイオプシー市場規模：エンドユーザー別&CAGR（2025～2032年）

リキッドバイオプシー市場規模&CAGR（2025～2032年）